Third-year clinician scientist at the Department of Neurology at LMU University Hospital in Munich, Germany, specializing in neurodegenerative diseases. I am invested in several projects researching new diagnostic and prognostic biomarkers for patients with Down Syndrome suffering from Alzheimer's disease and investigating the effect of sex as well as sociocultural- and care-related influences on pathophysiology, diagnosis and prognosis in patients with Alzheimer's disease and frontotemporal dementia.

I am a neuropathologist at Mt. Sinai in NY. My research interests include understanding the mechanisms by which some individuals are resistant to the development of AD pathology (including primary age-related tauopathy, PART) and how some are resilient against the cognitive decline typically associated with AD pathology. I'm also curious about the differences in the distribution of progression of p-tau pathology and its interactions with beta-amyloid.

Rebecca Wallings is a Postdoctoral Fellow in the lab of Professor Malú Tansey, CTRND, University of Florida. She completed her DPhil at the University of Oxford in 2018 under the supervision of Professor Richard Wade-Martins, Director of the Oxford Parkinson’s Disease Centre, and Dr. Natalie Connor-Robson. Her thesis focused on the role of LRRK2 in the autophagy pathway and identified a novel LRRK2-substrate, vATPase a1, with LRRK2-mutations disrupting this interaction and causing lysosomal dysfunction in neurons. Rebecca’s current research focuses on understanding how lysosomal and mitochondrial dysfunction contributes to dysregulated inflammation in PD and FTD, with keen interest in the role of LRRK2 and progranulin. More specifically, Rebecca's research has turned its focus towards a potential, rather surprising, role of immune cell exhaustion in neurodegenerative diseases. Importantly, Rebecca's research seeks to understand the dynamic changes of the immune system throughout the course of disease, from prodromal to progression, to improve the success of potential immune-modulatory therapies.

Tina is a PhD candidate at McGill University. She focuses on investigating the sex differences in Alzheimer's disease using neuroimaging, fluid biomarkers and genetics.

Dr. Watson is the CEO and Founder of Alzheimer’s Research and Treatment Center. He is an internationally recognized leading Certified Principal Investigator who has dedicated his career to conducting clinical trials for Alzheimer’s disease. He has participated in over 450 clinical research trials over the past 3 decades. His expertise in clinical research has contributed significantly to the field and his Centers are consistently the top enrolling sites in the world.

Carina Wattmo began work in the medical field as a Registered Nurse. Her broad background includes Bachelor of Science degrees in Business Administration and Statistics, and many years of work experience as a controller and medical statistician at the Psychogeriatric Clinic, Lund University Hospital, Lund and at the Neuropsychiatric Clinic, Malmö University Hospital, Malmö, Sweden. Wattmo became more interested in medical research and she obtained a PhD from Lund University in Medical Science, focusing on Alzheimer’s disease (AD) progression and the development of prediction models to estimate the cognitive and functional longitudinal outcomes in cholinesterase inhibitor-treated patients. She currently works as a researcher and is affiliated at the Cognitive Disorders Research Unit, Lund University. Wattmo continues to expand the dimensions of her research by investigating potential risk factors that affect various aspects of disease progression and endpoints in different subgroups of patients with AD, as well as developing empirical statistical models that may be useful in studies of future therapies. She attends several international conferences annually and gives oral communications and poster presentations. Wattmo also delivers lectures to physicians and health-care professionals working in the field of dementia, and to local politicians, the general public, and Rotary Club members, among others.